{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:29:04Z","timestamp":1794086944619,"version":"4.8.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010792","name":"Tungs' Taichung MetroHarbor Hospital","doi-asserted-by":"publisher","award":["TTMHH-R1130053"],"award-info":[{"award-number":["TTMHH-R1130053"]}],"id":[{"id":"10.13039\/100010792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mcpiqojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.mayocpiqo.2026.100709","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T06:07:15Z","timestamp":1772863635000},"page":"100709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Outcomes of Sodium-Glucose Cotransporter 2 Inhibitor Therapy in Nondiabetic Autosomal-Dominant Polycystic Kidney Disease: Effects on Progression to Dialysis in a TrinetX Cohort"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7221-8224","authenticated-orcid":false,"given":"Chia-Hua","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Chuan","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hsiang","family":"Kuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paik-Seong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu-Chi","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ru","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ci-Wen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6060-5659","authenticated-orcid":false,"given":"Tsai-Kun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 4","key":"10.1016\/j.mayocpiqo.2026.100709_bib1","doi-asserted-by":"crossref","first-page":"iv15","DOI":"10.1093\/ndt\/gfu017","article-title":"Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival\u2014an analysis of data from the ERA-EDTA Registry","volume":"29","author":"Spithoven","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"20","key":"10.1016\/j.mayocpiqo.2026.100709_bib2","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2026.100709_bib3","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s12882-022-02956-8","article-title":"A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease","volume":"23","author":"Mader","year":"2022","journal-title":"BMC Nephrol"},{"issue":"24","key":"10.1016\/j.mayocpiqo.2026.100709_bib4","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2026.100709_bib5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/ndt\/gfz290","article-title":"Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial","volume":"35","author":"Heerspink","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.mayocpiqo.2026.100709_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101163","article-title":"Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials","volume":"41","author":"Staplin","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2026.100709_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae186","article-title":"Dapagliflozin treatment in patients with chronic kidney disease associated with autosomal dominant polycystic kidney disease","volume":"17","author":"Yoshimoto","year":"2024","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2026.100709_bib8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabet Endocrinol"},{"issue":"12","key":"10.1016\/j.mayocpiqo.2026.100709_bib9","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/ndt\/gfaf061","article-title":"SGLT2 inhibition for patients with ADPKD\u2013closing the evidence gap","volume":"40","author":"M\u00fcller","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2026.100709_bib10","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.ekir.2025.01.023","article-title":"Open-label, randomized, controlled, crossover trial on the effect of dapagliflozin in patients with ADPKD receiving tolvaptan","volume":"10","author":"Uchiyama","year":"2025","journal-title":"Kidney Int Rep"},{"issue":"7","key":"10.1016\/j.mayocpiqo.2026.100709_bib11","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.0000000725","article-title":"Sodium-glucose cotransporter-2 inhibitor therapy and longitudinal changes in kidney function among veterans with autosomal dominant polycystic kidney disease","volume":"20","author":"Eswarappa","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.mayocpiqo.2026.100709_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/2054358116679130","article-title":"Positive predictive values of international classification of diseases, 10th revision coding algorithms to identify patients with autosomal dominant polycystic kidney disease","volume":"3","author":"Kalatharan","year":"2016","journal-title":"Can J Kidney Health Dis"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2026.100709_bib13","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2026.100709_bib14","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1053\/j.ajkd.2017.10.023","article-title":"Patterns of kidney function decline in autosomal dominant polycystic kidney disease: a post hoc analysis from the HALT-PKD trials","volume":"71","author":"Brosnahan","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2026.100709_bib15","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1053\/j.ajkd.2011.12.009","article-title":"Longitudinal progression trajectory of GFR among patients with CKD","volume":"59","author":"Li","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2026.100709_bib16","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s13730-025-00990-7","article-title":"Renoprotective effects of combination therapy with tolvaptan and dapagliflozin in autosomal dominant polycystic kidney disease: a four-case series","volume":"14","author":"Nishida","year":"2025","journal-title":"CEN Case Rep"},{"issue":"19","key":"10.1016\/j.mayocpiqo.2026.100709_bib17","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.3390\/jcm12196341","article-title":"Short-term dapagliflozin administration in autosomal dominant polycystic kidney disease-a retrospective single-arm case series study","volume":"12","author":"Morioka","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.mayocpiqo.2026.100709_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112357","article-title":"Impact of SGLT2 inhibitors on kidney health and survival in patients with polycystic kidney disease and type 2 diabetes","volume":"226","author":"Yen","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2026.100709_bib19","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.nefroe.2023.04.002","article-title":"The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: a systematic review and meta-analysis","volume":"43","author":"Li","year":"2023","journal-title":"Nefrologia (Engl Ed)"},{"issue":"25","key":"10.1016\/j.mayocpiqo.2026.100709_bib20","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2026.100709_bib21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2215\/CJN.09380822","article-title":"Kidney-protective effects of SGLT2 inhibitors","volume":"18","author":"Palmer","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.mayocpiqo.2026.100709_bib22","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.amjmed.2019.08.005","article-title":"Renal effects of sodium-glucose co-transporter inhibitors","volume":"132","author":"Thomson","year":"2019","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2026.100709_bib23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Group","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2026.100709_bib24","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1681\/ASN.2017070819","article-title":"Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease","volume":"29","author":"Nowak","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2026.100709_bib25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/ndt\/gft437","article-title":"Extra-renal manifestations of autosomal dominant polycystic kidney disease (ADPKD): considerations for routine screening and management","volume":"29","author":"Luciano","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2026.100709_bib26","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nm.3092","article-title":"Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy","volume":"19","author":"Rowe","year":"2013","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2026.100709_bib27","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.cmet.2019.09.012","article-title":"Ketosis ameliorates renal cyst growth in polycystic kidney disease","volume":"30","author":"Torres","year":"2019","journal-title":"Cell metabolism"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2026.100709_bib28","doi-asserted-by":"crossref","first-page":"F361","DOI":"10.1152\/ajprenal.00070.2022","article-title":"SGLT2 inhibitor and loop diuretic induce different vasopressin and fluid homeostatic responses in nondiabetic rats","volume":"323","author":"Masuda","year":"2022","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2026.100709_bib29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease","volume":"19","author":"Wang","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2026.100709_bib30","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.199","article-title":"Targeting of sodium\u2013glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han: SPRD rats","volume":"84","author":"Wang","year":"2013","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2026.100709_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125603","article-title":"Effect of sodium-glucose cotransport inhibition on polycystic kidney disease progression in PCK rats","volume":"10","author":"Kapoor","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2026.100709_bib32","doi-asserted-by":"crossref","first-page":"382","DOI":"10.7326\/0003-4819-159-6-201309170-00004","article-title":"Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease","volume":"159","author":"Erickson","year":"2013","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2026.100709_bib33","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.kint.2024.07.010","article-title":"KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary","volume":"107","author":"Torres","year":"2025","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2026.100709_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48638-9","article-title":"Real-life use of tolvaptan in ADPKD: a retrospective analysis of a large Canadian cohort","volume":"13","author":"Calvaruso","year":"2023","journal-title":"Sci Rep"}],"updated-by":[{"DOI":"10.1016\/j.mayocpiqo.2026.100737","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000}}],"container-title":["Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454826000160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454826000160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:51:34Z","timestamp":1781711494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2542454826000160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2542454826000160"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2026.100709","relation":{},"ISSN":["2542-4548"],"issn-type":[{"value":"2542-4548","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Outcomes of Sodium-Glucose Cotransporter 2 Inhibitor Therapy in Nondiabetic Autosomal-Dominant Polycystic Kidney Disease: Effects on Progression to Dialysis in a TrinetX Cohort","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings: Innovations, Quality & Outcomes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2026.100709","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research.","name":"copyright","label":"Copyright"}],"article-number":"100709"}}